At AGTC we are developing genetic therapies to treat patients with rare inherited conditions. Our most advanced therapy programs are designed to restore visual function and meet the needs of patients with rare blinding conditions.
Learn more
AGTC Receives Positive Type C Meeting Feedback from the FDA for the Company’s Design and Operating Procedures of its Planned cGMP Manufacturing Facility
AGTC Announces Pricing of $10 Million Underwritten Public Offering
AGTC Announces Positive Three-Month Interim Results from Skyline Trial of AGTC-501 for the Treatment of X-Linked Retinitis Pigmentosa
At AGTC we are focused on genetic therapies that can restore visual function in patients with rare inherited conditions. Simple activities such as riding a bike, playing outside, and even the ability to recognize a loved one in a crowd, can be impossible for patients with rare blinding conditions. Our treatment candidates have the potential to dramatically improve visual function in patients with conditions where only palliative or no therapies exist today.
Fifteen years of gene therapy experience allows us at AGTC to design and construct all critical gene therapy elements and bring them together to develop successful treatments for patients.
© agtc. All rights reserved.
AGTC is now pre-screening for a phase 2/3 clinical trial of an investigational gene therapy in people with X-Linked Retinitis Pigmentosa.
Learn more about the clinical trial or how to qualify for pre-screening:
